FDA classifies von Willebrand factor assay as a lower-risk medical device
/ 1 min read
Table of Contents
The Food and Drug Administration has officially classified the von Willebrand factor assay into Class II. This classification covers tests that measure von Willebrand factor activity or size distribution in human plasma to help diagnose related disorders.
Why it matters: This is primarily an administrative update that reduces regulatory hurdles for manufacturers of these specific blood tests. By lowering the classification, the FDA aims to speed up access to diagnostic tools for von Willebrand disease while maintaining oversight through required labeling and testing protocols. It does not change how doctors use the tests or alter patient care standards directly.
Who it affects
- Medical device manufacturers seeking to market von Willebrand factor assays in the United States
This action was issued by the Food and Drug Administration under the Department of Health and Human Services; readers should consult the original Federal Register document for full regulatory details.
Agency: Health and Human Services Department, Food and Drug Administration
Source: Federal Register — read the official document